SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 10/29/20 Amgen Inc. 10-Q 9/30/20 78:11M |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 1.29M 2: EX-10.41 Amendment No. 2 to Collaboration Agreement HTML 37K 3: EX-10.46 Restated Amendment No. 2 to Share Purchase HTML 48K Agreement 4: EX-31 Rule 13A-14(A) Certifications HTML 31K 5: EX-32 Section 1350 Certifications HTML 25K 12: R1 Cover Page HTML 83K 13: R2 Condensed Consolidated Statements of Comprehensive HTML 49K Income 14: R3 Condensed Consolidated Statements of Income HTML 94K 15: R4 Condensed Consolidated Balance Sheets HTML 97K 16: R5 Condensed Consolidated Balance Sheets HTML 27K (Parenthetical) 17: R6 Condensed Consolidated Statements of Stockholders' HTML 108K Equity 18: R7 Condensed Consolidated Statements of Stockholders' HTML 23K Equity (Parenthetical) 19: R8 Condensed Consolidated Statements of Cash Flows HTML 94K 20: R9 Summary of significant accounting policies HTML 31K 21: R10 Revenues HTML 102K 22: R11 Income taxes HTML 30K 23: R12 Earnings per share HTML 43K 24: R13 Collaborations HTML 26K 25: R14 Investments HTML 93K 26: R15 Inventories HTML 28K 27: R16 Goodwill and other intangible assets HTML 55K 28: R17 Financing arrangements HTML 102K 29: R18 Stockholders' equity HTML 115K 30: R19 Fair value measurement HTML 125K 31: R20 Derivative instruments HTML 162K 32: R21 Contingencies and commitments HTML 41K 33: R22 Summary of significant accounting policies HTML 48K (Policies) 34: R23 Revenues (Tables) HTML 99K 35: R24 Earnings per share (Tables) HTML 41K 36: R25 Investments (Tables) HTML 87K 37: R26 Inventories (Tables) HTML 29K 38: R27 Goodwill and other intangible assets (Tables) HTML 54K 39: R28 Financing arrangements (Tables) HTML 101K 40: R29 Stockholders' equity (Tables) HTML 117K 41: R30 Fair value measurement (Tables) HTML 115K 42: R31 Derivative instruments (Tables) HTML 160K 43: R32 Summary of significant accounting policies HTML 26K (Details) 44: R33 Revenues (Details) HTML 90K 45: R34 Income taxes (Details) HTML 25K 46: R35 Earnings per share (Details) HTML 51K 47: R36 Collaborations (Details) HTML 32K 48: R37 Investments (Details) HTML 57K 49: R38 Investments (Fair Values by Classification) HTML 31K (Details) 50: R39 Investments (Available-for-sale Investments) HTML 28K (Details Textual) 51: R40 Investments (Fair Values by Contractual Maturity) HTML 33K (Details) 52: R41 Investments (Equity Securities) (Details Textual) HTML 28K 53: R42 Investments Investments (Limited Partnership HTML 60K Investments) (Details) 54: R43 Inventories (Details) HTML 30K 55: R44 Goodwill and other intangible assets (Goodwill HTML 26K Roll Forward) (Details) 56: R45 Goodwill and other intangible assets (Identifiable HTML 51K Intangible Assets) (Details) 57: R46 Goodwill and other intangible assets (Details HTML 38K Textual) 58: R47 Financing arrangements (Principal Amounts and HTML 218K Carrying Value of Long-term Borrowings) (Details) 59: R48 Financing arrangements (Details Textual) HTML 88K 60: R49 Financing arrangements (Schedule Interest Rate HTML 61K Swaps) (Details) 61: R50 Financing arrangements (Interest Rate Swaps HTML 64K Textual) (Details) 62: R51 Financing arrangements (Debt exchange) (Details) HTML 55K 63: R52 Stockholders' equity (Share Repurchase Program) HTML 28K (Details) 64: R53 Stockholders' equity (Details Textual) (Details) HTML 37K 65: R54 Stockholders' equity (Components of AOCI) HTML 60K (Details) 66: R55 Stockholders' equity (Reclassifications out of HTML 69K AOCI) (Details) 67: R56 Fair value measurement (Details) HTML 124K 68: R57 Fair value measurement (Details Textual) HTML 28K 69: R58 Derivative instruments (Details Textual) HTML 54K 70: R59 Derivative instruments (Cross-currency Swaps) HTML 55K (Details) 71: R60 Derivative instruments (Effective Portion of HTML 30K Unrealized Gain (Loss)) (Details) 72: R61 Derivative instruments (Hedged Liabilities and HTML 35K Cumulative Amount) (Details) 73: R62 Derivative instruments (Summary of Income and HTML 47K Expense Line Items) (Details) 74: R63 Derivative instruments (Fair Value of Derivatives) HTML 51K (Details) 76: XML IDEA XML File -- Filing Summary XML 142K 11: XML XBRL Instance -- amgn-20200930_htm XML 3.65M 75: EXCEL IDEA Workbook of Financial Reports XLSX 105K 7: EX-101.CAL XBRL Calculations -- amgn-20200930_cal XML 196K 8: EX-101.DEF XBRL Definitions -- amgn-20200930_def XML 836K 9: EX-101.LAB XBRL Labels -- amgn-20200930_lab XML 1.64M 10: EX-101.PRE XBRL Presentations -- amgn-20200930_pre XML 1.06M 6: EX-101.SCH XBRL Schema -- amgn-20200930 XSD 178K 77: JSON XBRL Instance as JSON Data -- MetaLinks 377± 541K 78: ZIP XBRL Zipped Folder -- 0000318154-20-000060-xbrl Zip 374K
amgn-20200930 |
i ☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
i ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
i Delaware | i 95-3540776 | |||||||
(State
or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||||
i One Amgen Center Drive | i 91320-1799 | |||||||
i Thousand Oaks | ||||||||
i California | ||||||||
(Address of principal executive offices) | (Zip Code) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
i Common stock, $0.0001 par value | i AMGN | i The NASDAQ Global Select Market | ||||||
i 1.250% Senior Notes Due 2022 | i AMGN22 | i New York Stock Exchange | ||||||
i 2.00% Senior Notes Due 2026 | i AMGN26 | i New York Stock Exchange |
i Large accelerated filer | ☑ | Accelerated filer | ☐ | Non-accelerated filer | ☐ | ||||||||||||
Smaller reporting company | i ☐ | Emerging growth company | i ☐ |
Page No. | ||||||||
Item 1. | ||||||||
Item 2. | ||||||||
Item 3. | ||||||||
Item 4. | ||||||||
Item 1. | ||||||||
Item 1A. | ||||||||
Item 2. | ||||||||
Item 6. | ||||||||
Item 1. | FINANCIAL STATEMENTS |
Three
months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||
2020 | 2019 | 2020 | 2019 | ||||||||||||||||||||
Revenues: | |||||||||||||||||||||||
Product sales | $ | i 6,104 | $ | i 5,463 | $ | i 17,906 | $ | i 16,323 | |||||||||||||||
Other revenues | i 319 | i 274 | i 884 | i 842 | |||||||||||||||||||
Total revenues | i 6,423 | i 5,737 | i 18,790 | i 17,165 | |||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||
Cost of sales | i 1,561 | i 1,036 | i 4,562 | i 3,103 | |||||||||||||||||||
Research and development | i 1,062 | i 1,001 | i 2,978 | i 2,804 | |||||||||||||||||||
Selling, general and administrative | i 1,346 | i 1,223 | i 3,957 | i 3,637 | |||||||||||||||||||
Other | i 1 | i 1 | i 162 | ( i 5) | |||||||||||||||||||
Total operating expenses | i 3,970 | i 3,261 | i 11,659 | i 9,539 | |||||||||||||||||||
Operating income | i 2,453 | i 2,476 | i 7,131 | i 7,626 | |||||||||||||||||||
Interest expense, net | i 302 | i 313 | i 944 | i 988 | |||||||||||||||||||
Interest and other income, net | i 55 | i 114 | i 69 | i 517 | |||||||||||||||||||
Income before income taxes | i 2,206 | i 2,277 | i 6,256 | i 7,155 | |||||||||||||||||||
Provision for income taxes | i 185 | i 309 | i 607 | i 1,016 | |||||||||||||||||||
Net income | $ | i 2,021 | $ | i 1,968 | $ | i 5,649 | $ | i 6,139 | |||||||||||||||
Earnings per share: | |||||||||||||||||||||||
Basic | $ | i 3.45 | $ | i 3.29 | $ | i 9.61 | $ | i 10.08 | |||||||||||||||
Diluted | $ | i 3.43 | $ | i 3.27 | $ | i 9.54 | $ | i 10.01 | |||||||||||||||
Shares used in calculation of earnings per share: | |||||||||||||||||||||||
Basic | i 585 | i 599 | i 588 | i 609 | |||||||||||||||||||
Diluted | i 589 | i 602 | i 592 | i 613 |
Three
months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||
2020 | 2019 | 2020 | 2019 | ||||||||||||||||||||
Net income | $ | i 2,021 | $ | i 1,968 | $ | i 5,649 | $ | i 6,139 | |||||||||||||||
Other
comprehensive (loss) income, net of reclassification adjustments and taxes: | |||||||||||||||||||||||
Gains (losses) on foreign currency translation | i 14 | ( i 39) | ( i 41) | ( i 56) | |||||||||||||||||||
(Losses) gains on cash flow hedges | ( i 128) | i 86 | ( i 305) | i 27 | |||||||||||||||||||
Gains (losses) on available-for-sale securities | i 1 | i 30 | ( i 20) | i 404 | |||||||||||||||||||
Other | ( i 7) | i — | ( i 9) | i 6 | |||||||||||||||||||
Other comprehensive (loss) income, net of taxes | ( i 120) | i 77 | ( i 375) | i 381 | |||||||||||||||||||
Comprehensive income | $ | i 1,901 | $ | i 2,045 | $ | i 5,274 | $ | i 6,520 |
September 30, 2020 | December 31, 2019 | ||||||||||
(Unaudited) | |||||||||||
ASSETS | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | i 9,087 | $ | i 6,037 | |||||||
Marketable securities | i 3,273 | i 2,874 | |||||||||
Trade receivables, net | i 4,094 | i 4,057 | |||||||||
Inventories | i 3,942 | i 3,584 | |||||||||
Other current assets | i 2,265 | i 1,888 | |||||||||
Total current assets | i 22,661 | i 18,440 | |||||||||
Property, plant and equipment, net | i 4,816 | i 4,928 | |||||||||
Intangible assets, net | i 17,254 | i 19,413 | |||||||||
Goodwill | i 14,674 | i 14,703 | |||||||||
Other assets | i 5,232 | i 2,223 | |||||||||
Total assets | $ | i 64,637 | $ | i 59,707 | |||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
Current liabilities: | |||||||||||
Accounts payable | $ | i 1,161 | $ | i 1,371 | |||||||
Accrued liabilities | i 8,701 | i 8,511 | |||||||||
Current portion of long-term debt | i 91 | i 2,953 | |||||||||
Total current liabilities | i 9,953 | i 12,835 | |||||||||
Long-term debt | i 34,196 | i 26,950 | |||||||||
Long-term deferred tax liabilities | i 210 | i 606 | |||||||||
Long-term tax liabilities | i 7,560 | i 8,037 | |||||||||
Other noncurrent liabilities | i 1,759 | i 1,606 | |||||||||
Contingencies and commitments | i | i | |||||||||
Stockholders’ equity: | |||||||||||
Common stock and additional paid-in capital; $ i i 0.0001 /
par value; i i 2,750.0 / shares authorized;
outstanding — i 583.5 shares in 2020 and i 591.4 shares in 2019 | i 31,713 | i 31,531 | |||||||||
Accumulated deficit | ( i 19,851) | ( i 21,330) | |||||||||
Accumulated other comprehensive loss | ( i 903) | ( i 528) | |||||||||
Total stockholders’ equity | i 10,959 | i 9,673 | |||||||||
Total liabilities and stockholders’ equity | $ | i 64,637 | $ | i 59,707 |
Number of shares of common stock | Common stock and additional paid-in capital | Accumulated deficit | Accumulated other comprehensive loss | Total | |||||||||||||||||||||||||
Balance as of December 31, 2019 | i 591.4 | $ | i 31,531 | $ | ( i 21,330) | $ | ( i 528) | $ | i 9,673 | ||||||||||||||||||||
Cumulative
effect of changes in accounting principles, net of tax | — | — | ( i 2) | — | ( i 2) | ||||||||||||||||||||||||
Net income | — | — | i 1,825 | — | i 1,825 | ||||||||||||||||||||||||
Other
comprehensive loss, net of taxes | — | — | — | ( i 134) | ( i 134) | ||||||||||||||||||||||||
Dividends
declared on common stock ($ i 1.60 per share) | — | — | ( i 938) | — | ( i 938) | ||||||||||||||||||||||||
Issuance
of common stock in connection with the Company’s equity award programs | i 0.9 | i 10 | — | — | i 10 | ||||||||||||||||||||||||
Stock-based compensation expense | — | i 52 | — | — | i 52 | ||||||||||||||||||||||||
Tax
impact related to employee stock-based compensation expense | — | ( i 68) | — | — | ( i 68) | ||||||||||||||||||||||||
Repurchases of common stock | ( i 4.3) | — | ( i 933) | — | ( i 933) | ||||||||||||||||||||||||
Balance as of March 31, 2020 | i 588.0 | i 31,525 | ( i 21,378) | ( i 662) | i 9,485 | ||||||||||||||||||||||||
Net income | — | — | i 1,803 | — | i 1,803 | ||||||||||||||||||||||||
Other comprehensive loss, net of taxes | — | — | — | ( i 121) | ( i 121) | ||||||||||||||||||||||||
Issuance
of common stock in connection with the Company’s equity award programs | i 1.0 | i 65 | — | — | i 65 | ||||||||||||||||||||||||
Stock-based compensation expense | — | i 101 | — | — | i 101 | ||||||||||||||||||||||||
Tax
impact related to employee stock-based compensation expense | — | ( i 81) | — | — | ( i 81) | ||||||||||||||||||||||||
Repurchases of common stock | ( i 2.6) | — | ( i 591) | — | ( i 591) | ||||||||||||||||||||||||
Other | — | — | ( i 2) | — | ( i 2) | ||||||||||||||||||||||||
Balance as of June 30, 2020 | i 586.4 | i 31,610 | ( i 20,168) | ( i 783) | i 10,659 | ||||||||||||||||||||||||
Net income | — | — | i 2,021 | — | i 2,021 | ||||||||||||||||||||||||
Other comprehensive loss, net of taxes | — | — | — | ( i 120) | ( i 120) | ||||||||||||||||||||||||
Dividends
declared on common stock ($ i 1.60 per share) | — | — | ( i 952) | — | ( i 952) | ||||||||||||||||||||||||
Issuance
of common stock in connection with the Company’s equity award programs | i 0.1 | i 5 | — | — | i 5 | ||||||||||||||||||||||||
Stock-based compensation expense | — | i 109 | — | — | i 109 | ||||||||||||||||||||||||
Tax
impact related to employee stock-based compensation expense | — | ( i 11) | — | — | ( i 11) | ||||||||||||||||||||||||
Repurchases of common stock | ( i 3.0) | — | ( i 752) | — | ( i 752) | ||||||||||||||||||||||||
Balance as of September 30, 2020 | i 583.5 | $ | i 31,713 | $ | ( i 19,851) | $ | ( i 903) | $ | i 10,959 |
Number of shares of common stock | Common stock and additional paid-in capital | Accumulated deficit | Accumulated other comprehensive loss | Total | |||||||||||||||||||||||||
Balance as of December 31, 2018 | i 629.6 | $ | i 31,246 | $ | ( i 17,977) | $ | ( i 769) | $ | i 12,500 | ||||||||||||||||||||
Net income | — | — | i 1,992 | — | i 1,992 | ||||||||||||||||||||||||
Other
comprehensive income, net of taxes | — | — | — | i 253 | i 253 | ||||||||||||||||||||||||
Dividends
declared on common stock ($ i 1.45 per share) | — | — | ( i 879) | — | ( i 879) | ||||||||||||||||||||||||
Issuance
of common stock in connection with the Company’s equity award programs | i 0.7 | i 6 | — | — | i 6 | ||||||||||||||||||||||||
Stock-based compensation expense | — | i 64 | — | — | i 64 | ||||||||||||||||||||||||
Tax
impact related to employee stock-based compensation expense | — | ( i 73) | — | — | ( i 73) | ||||||||||||||||||||||||
Repurchases of common stock | ( i 15.9) | — | ( i 3,031) | — | ( i 3,031) | ||||||||||||||||||||||||
Balance as of March 31, 2019 | i 614.4 | i 31,243 | ( i 19,895) | ( i 516) | i 10,832 | ||||||||||||||||||||||||
Net income | — | — | i 2,179 | — | i 2,179 | ||||||||||||||||||||||||
Other comprehensive income, net of taxes | — | — | — | i 51 | i 51 | ||||||||||||||||||||||||
Issuance
of common stock in connection with the Company’s equity award programs | i 0.8 | i 23 | — | — | i 23 | ||||||||||||||||||||||||
Stock-based compensation expense | — | i 97 | — | — | i 97 | ||||||||||||||||||||||||
Tax
impact related to employee stock-based compensation expense | — | ( i 50) | — | — | ( i 50) | ||||||||||||||||||||||||
Repurchases of common stock | ( i 13.1) | — | ( i 2,349) | — | ( i 2,349) | ||||||||||||||||||||||||
Other | — | — | i 11 | — | i 11 | ||||||||||||||||||||||||
Balance as of June 30, 2019 | i 602.1 | i 31,313 | ( i 20,054) | ( i 465) | i 10,794 | ||||||||||||||||||||||||
Net income | — | — | i 1,968 | — | i 1,968 | ||||||||||||||||||||||||
Other
comprehensive income, net of taxes | — | — | — | i 77 | i 77 | ||||||||||||||||||||||||
Dividends
declared on common stock ($ i 1.45 per share) | — | — | ( i 880) | — | ( i 880) | ||||||||||||||||||||||||
Issuance
of common stock in connection with the Company’s equity award programs | i 0.3 | i 37 | — | — | i 37 | ||||||||||||||||||||||||
Stock-based compensation expense | — | i 108 | — | — | i 108 | ||||||||||||||||||||||||
Tax
impact related to employee stock-based compensation expense | — | ( i 7) | — | — | ( i 7) | ||||||||||||||||||||||||
Repurchases of common stock | ( i 6.2) | — | ( i 1,170) | — | ( i 1,170) | ||||||||||||||||||||||||
Balance as of September 30, 2019 | i 596.2 | $ | i 31,451 | $ | ( i 20,136) | $ | ( i 388) | $ | i 10,927 |
Nine
months ended September 30, | |||||||||||
2020 | 2019 | ||||||||||
Cash flows from operating activities: | |||||||||||
Net income | $ | i 5,649 | $ | i 6,139 | |||||||
Depreciation, amortization and other | i 2,728 | i 1,504 | |||||||||
Deferred income taxes | ( i 339) | ( i 172) | |||||||||
Other items, net | i 270 | i 169 | |||||||||
Changes in operating assets and liabilities, net of acquisition: | |||||||||||
Trade receivables, net | ( i 31) | ( i 63) | |||||||||
Inventories | ( i 316) | ( i 101) | |||||||||
Other assets | i 64 | ( i 269) | |||||||||
Accounts payable | ( i 202) | ( i 196) | |||||||||
Accrued income taxes, net | ( i 301) | ( i 128) | |||||||||
Long-term tax liabilities | i 110 | ( i 262) | |||||||||
Other liabilities | i 712 | i 15 | |||||||||
Net cash provided by operating activities | i 8,344 | i 6,636 | |||||||||
Cash flows from investing activities: | |||||||||||
Purchases of marketable securities | ( i 5,329) | ( i 9,062) | |||||||||
Proceeds from sales of marketable securities | i 2,597 | i 3,019 | |||||||||
Proceeds from maturities of marketable securities | i 2,338 | i 18,441 | |||||||||
Purchases of property, plant and equipment | ( i 435) | ( i 430) | |||||||||
Purchases of equity method investments | ( i 3,154) | ( i 14) | |||||||||
Other | ( i 34) | ( i 282) | |||||||||
Net cash (used in) provided by investing activities | ( i 4,017) | i 11,672 | |||||||||
Cash flows from financing activities: | |||||||||||
Net proceeds from issuance of debt | i 8,914 | i — | |||||||||
Repayment of debt | ( i 5,000) | ( i 4,514) | |||||||||
Repurchases of common stock | ( i 2,281) | ( i 6,608) | |||||||||
Dividends paid | ( i 2,823) | ( i 2,649) | |||||||||
Other | ( i 87) | ( i 67) | |||||||||
Net cash used in financing activities | ( i 1,277) | ( i 13,838) | |||||||||
Increase in cash and cash equivalents | i 3,050 | i 4,470 | |||||||||
Cash and cash equivalents at beginning of period | i 6,037 | i 6,945 | |||||||||
Cash and cash equivalents at end of period | $ | i 9,087 | $ | i 11,415 |
Three months ended September 30, | ||||||||||||||||||||||||||||||||||||||
2020 | 2019 | |||||||||||||||||||||||||||||||||||||
U.S. | ROW | Total | U.S. | ROW | Total | |||||||||||||||||||||||||||||||||
Enbrel® (etanercept) | $ | i 1,289 | $ | i 36 | $ | i 1,325 | $ | i 1,323 | $ | i 43 | $ | i 1,366 | ||||||||||||||||||||||||||
Prolia®
(denosumab) | i 478 | i 223 | i 701 | i 425 | i 205 | i 630 | ||||||||||||||||||||||||||||||||
Neulasta®
(pegfilgrastim) | i 484 | i 71 | i 555 | i 619 | i 92 | i 711 | ||||||||||||||||||||||||||||||||
Otezla®
(apremilast) | i 439 | i 99 | i 538 | i — | i — | i — | ||||||||||||||||||||||||||||||||
XGEVA®
(denosumab) | i 363 | i 118 | i 481 | i 356 | i 120 | i 476 | ||||||||||||||||||||||||||||||||
Aranesp®
(darbepoetin alfa) | i 158 | i 226 | i 384 | i 204 | i 248 | i 452 | ||||||||||||||||||||||||||||||||
KYPROLIS®
(carfilzomib) | i 173 | i 87 | i 260 | i 163 | i 103 | i 266 | ||||||||||||||||||||||||||||||||
Repatha®
(evolocumab) | i 92 | i 113 | i 205 | i 85 | i 83 | i 168 | ||||||||||||||||||||||||||||||||
Other products | i 1,142 | i 513 | i 1,655 | i 854 | i 540 | i 1,394 | ||||||||||||||||||||||||||||||||
Total
product sales(1) | $ | i 4,618 | $ | i 1,486 | i 6,104 | $ | i 4,029 | $ | i 1,434 | i 5,463 | ||||||||||||||||||||||||||||
Other revenues | i 319 | i 274 | ||||||||||||||||||||||||||||||||||||
Total revenues | $ | i 6,423 | $ | i 5,737 |
Nine months ended September 30, | ||||||||||||||||||||||||||||||||||||||
2020 | 2019 | |||||||||||||||||||||||||||||||||||||
U.S. | ROW | Total | U.S. | ROW | Total | |||||||||||||||||||||||||||||||||
ENBREL | $ | i 3,619 | $ | i 105 | $ | i 3,724 | $ | i 3,744 | $ | i 136 | $ | i 3,880 | ||||||||||||||||||||||||||
Prolia® | i 1,341 | i 673 | i 2,014 | i 1,273 | i 647 | i 1,920 | ||||||||||||||||||||||||||||||||
Neulasta® | i 1,538 | i 219 | i 1,757 | i 2,231 | i 325 | i 2,556 | ||||||||||||||||||||||||||||||||
Otezla® | i 1,280 | i 298 | i 1,578 | i — | i — | i — | ||||||||||||||||||||||||||||||||
XGEVA®
| i 1,036 | i 361 | i 1,397 | i 1,091 | i 355 | i 1,446 | ||||||||||||||||||||||||||||||||
Aranesp® | i 489 | i 704 | i 1,193 | i 578 | i 724 | i 1,302 | ||||||||||||||||||||||||||||||||
KYPROLIS® | i 527 | i 266 | i 793 | i 483 | i 295 | i 778 | ||||||||||||||||||||||||||||||||
Repatha® | i 331 | i 303 | i 634 | i 259 | i 202 | i 461 | ||||||||||||||||||||||||||||||||
Other products | i 3,164 | i 1,652 | i 4,816 | i 2,503 | i 1,477 | i 3,980 | ||||||||||||||||||||||||||||||||
Total
product sales(1) | $ | i 13,325 | $ | i 4,581 | i 17,906 | $ | i 12,162 | $ | i 4,161 | i 16,323 | ||||||||||||||||||||||||||||
Other revenues | i 884 | i 842 | ||||||||||||||||||||||||||||||||||||
Total revenues | $ | i 18,790 | $ | i 17,165 |
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||
2020 | 2019 | 2020 | 2019 | ||||||||||||||||||||
Income (Numerator): | |||||||||||||||||||||||
Net income for basic and diluted EPS | $ | i 2,021 | $ | i 1,968 | $ | i 5,649 | $ | i 6,139 | |||||||||||||||
Shares (Denominator): | |||||||||||||||||||||||
Weighted-average shares for basic EPS | i 585 | i 599 | i 588 | i 609 | |||||||||||||||||||
Effect of dilutive securities | i 4 | i 3 | i 4 | i 4 | |||||||||||||||||||
Weighted-average shares for diluted EPS | i 589 | i 602 | i 592 | i 613 | |||||||||||||||||||
Basic EPS | $ | i 3.45 | $ | i 3.29 | $ | i 9.61 | $ | i 10.08 | |||||||||||||||
Diluted EPS | $ | i 3.43 | $ | i 3.27 | $ | i 9.54 | $ | i 10.01 |
Types of securities as of September 30, 2020 | Amortized cost | Gross unrealized gains | Gross unrealized losses | Fair values | ||||||||||||||||||||||
U.S. Treasury notes | $ | i 172 | $ | i 2 | $ | i — | $ | i 174 | ||||||||||||||||||
U.S. Treasury bills | i 6,399 | i — | i — | i 6,399 | ||||||||||||||||||||||
Corporate debt securities: | ||||||||||||||||||||||||||
Financial | i — | i — | i — | i — | ||||||||||||||||||||||
Industrial | i — | i — | i — | i — | ||||||||||||||||||||||
Other | i — | i — | i — | i — | ||||||||||||||||||||||
Residential-mortgage-backed securities | i — | i — | i — | i — | ||||||||||||||||||||||
Money market mutual funds | i 5,016 | i — | i — | i 5,016 | ||||||||||||||||||||||
Other short-term interest-bearing securities | i — | i — | i — | i — | ||||||||||||||||||||||
Total interest-bearing securities | $ | i 11,587 | $ | i 2 | $ | i — | $ | i 11,589 |
Types of securities as of December 31, 2019 | Amortized cost | Gross unrealized gains | Gross unrealized losses | Fair values | ||||||||||||||||||||||
U.S. Treasury notes | $ | i 359 | $ | i 1 | $ | i — | $ | i 360 | ||||||||||||||||||
U.S. Treasury bills | i — | i — | i — | i — | ||||||||||||||||||||||
Corporate debt securities: | ||||||||||||||||||||||||||
Financial | i 1,108 | i 13 | i — | i 1,121 | ||||||||||||||||||||||
Industrial | i 824 | i 10 | i — | i 834 | ||||||||||||||||||||||
Other | i 195 | i 3 | i — | i 198 | ||||||||||||||||||||||
Residential-mortgage-backed securities | i 181 | i 1 | i — | i 182 | ||||||||||||||||||||||
Money market mutual funds | i 5,250 | i — | i — | i 5,250 | ||||||||||||||||||||||
Other short-term interest-bearing securities | i 289 | i — | i — | i 289 | ||||||||||||||||||||||
Total interest-bearing securities | $ | i 8,206 | $ | i 28 | $ | i — | $ | i 8,234 |
Condensed Consolidated Balance Sheets locations | September 30, 2020 | December 31, 2019 | ||||||||||||
Cash and cash equivalents | $ | i 8,316 | $ | i 5,360 | ||||||||||
Marketable securities | i 3,273 | i 2,874 | ||||||||||||
Total interest-bearing securities | $ | i 11,589 | $ | i 8,234 |
Contractual maturities | September 30, 2020 | December 31, 2019 | ||||||||||||
Maturing in one year or less | $ | i 11,536 | $ | i 5,629 | ||||||||||
Maturing after one year through three years | i 53 | i 2,304 | ||||||||||||
Maturing after three years through five years | i — | i 119 | ||||||||||||
Residential-mortgage-backed securities | i — | i 182 | ||||||||||||
Total interest-bearing securities | $ | i 11,589 | $ | i 8,234 |
September 30, 2020 | December 31, 2019 | ||||||||||
Raw materials | $ | i 496 | $ | i 358 | |||||||
Work in process | i 2,551 | i 2,227 | |||||||||
Finished goods | i 895 | i 999 | |||||||||
Total inventories | $ | i 3,942 | $ | i 3,584 |
Nine
months ended September 30, 2020 | |||||
Beginning balance | $ | i 14,703 | |||
Currency translation adjustment | ( i 29) | ||||
Ending balance | $ | i 14,674 |
September 30, 2020 | December 31, 2019 | ||||||||||||||||||||||||||||||||||
Gross carrying amounts | Accumulated amortization | Other intangible assets, net | Gross carrying amounts | Accumulated amortization | Other intangible assets, net | ||||||||||||||||||||||||||||||
Finite-lived intangible assets: | |||||||||||||||||||||||||||||||||||
Developed-product-technology rights | $ | i 25,572 | $ | ( i 9,998) | $ | i 15,574 | $ | i 25,575 | $ | ( i 8,322) | $ | i 17,253 | |||||||||||||||||||||||
Licensing rights | i 3,747 | ( i 2,710) | i 1,037 | i 3,761 | ( i 2,398) | i 1,363 | |||||||||||||||||||||||||||||
Marketing-related rights | i 1,365 | ( i 1,019) | i 346 | i 1,382 | ( i 965) | i 417 | |||||||||||||||||||||||||||||
Research and development technology rights | i 1,295 | ( i 1,028) | i 267 | i 1,273 | ( i 947) | i 326 | |||||||||||||||||||||||||||||
Total
finite-lived intangible assets | i 31,979 | ( i 14,755) | i 17,224 | i 31,991 | ( i 12,632) | i 19,359 | |||||||||||||||||||||||||||||
Indefinite-lived
intangible assets: | |||||||||||||||||||||||||||||||||||
In-process research and development | i 30 | — | i 30 | i 54 | — | i 54 | |||||||||||||||||||||||||||||
Total other intangible assets | $ | i 32,009 | $ | ( i 14,755) | $ | i 17,254 | $ | i 32,045 | $ | ( i 12,632) | $ | i 19,413 |
September 30, 2020 | December 31, 2019 | ||||||||||
i 4.50%
notes due 2020 (4.50% 2020 Notes) | $ | — | $ | i 300 | |||||||
i 2.125%
notes due 2020 (2.125% 2020 Notes) | i — | i 750 | |||||||||
Floating Rate Notes due 2020 | i — | i 300 | |||||||||
i 2.20%
notes due 2020 (2.20% 2020 Notes) | i — | i 700 | |||||||||
i 3.45%
notes due 2020 (3.45% 2020 Notes) | — | i 900 | |||||||||
i 4.10%
notes due 2021 (4.10% 2021 Notes) | — | i 1,000 | |||||||||
i 1.85%
notes due 2021 (1.85% 2021 Notes) | i — | i 750 | |||||||||
i 3.875%
notes due 2021 (3.875% 2021 Notes) | i 1,450 | i 1,750 | |||||||||
i 1.25%
€ i 1,250 million notes due 2022 (1.25% 2022 euro Notes) | i 1,465 | i 1,402 | |||||||||
i 2.70%
notes due 2022 (2.70% 2022 Notes) | i 500 | i 500 | |||||||||
i 2.65%
notes due 2022 (2.65% 2022 Notes) | i 1,500 | i 1,500 | |||||||||
i 3.625%
notes due 2022 (3.625% 2022 Notes) | i 750 | i 750 | |||||||||
i 0.41%
CHF i 700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) | i 760 | i 725 | |||||||||
i 2.25%
notes due 2023 (2.25% 2023 Notes) | i 750 | i 750 | |||||||||
i 3.625%
notes due 2024 (3.625% 2024 Notes) | i 1,400 | i 1,400 | |||||||||
i 1.90%
notes due 2025 (1.90% 2025 Notes) | i 500 | — | |||||||||
i 3.125%
notes due 2025 (3.125% 2025 Notes) | i 1,000 | i 1,000 | |||||||||
i 2.00%
€ i 750 million notes due 2026 (2.00% 2026 euro Notes) | i 879 | i 841 | |||||||||
i 2.60%
notes due 2026 (2.60% 2026 Notes) | i 1,250 | i 1,250 | |||||||||
i 5.50%
£ i 475 million notes due 2026 (5.50% 2026 pound sterling Notes) | i 614 | i 630 | |||||||||
i 2.20%
notes due 2027 (2.20% 2027 Notes) | i 1,750 | — | |||||||||
i 3.20%
notes due 2027 (3.20% 2027 Notes) | i 1,000 | i 1,000 | |||||||||
i 4.00%
£ i 700 million notes due 2029 (4.00% 2029 pound sterling Notes) | i 904 | i 928 | |||||||||
i 2.45%
notes due 2030 (2.45% 2030 Notes) | i 1,250 | — | |||||||||
i 2.30%
notes due 2031 (2.30% 2031 Notes) | i 1,250 | — | |||||||||
i 6.375%
notes due 2037 (6.375% 2037 Notes) | i 478 | i 552 | |||||||||
i 6.90%
notes due 2038 (6.90% 2038 Notes) | i 254 | i 291 | |||||||||
i 6.40%
notes due 2039 (6.40% 2039 Notes) | i 333 | i 466 | |||||||||
i 3.15%
notes due 2040 (3.15% 2040 Notes) | i 2,000 | — | |||||||||
i 5.75%
notes due 2040 (5.75% 2040 Notes) | i 373 | i 412 | |||||||||
i 4.95%
notes due 2041 (4.95% 2041 Notes) | i 600 | i 600 | |||||||||
i 5.15%
notes due 2041 (5.15% 2041 Notes) | i 729 | i 974 | |||||||||
i 5.65%
notes due 2042 (5.65% 2042 Notes) | i 415 | i 487 | |||||||||
i 5.375%
notes due 2043 (5.375% 2043 Notes) | i 185 | i 261 | |||||||||
i 4.40%
notes due 2045 (4.40% 2045 Notes) | i 2,250 | i 2,250 | |||||||||
i 4.563%
notes due 2048 (4.563% 2048 Notes) | i 1,415 | i 1,415 | |||||||||
i 3.375%
notes due 2050 (3.375% 2050 Notes) | i 2,250 | — | |||||||||
i 4.663%
notes due 2051 (4.663% 2051 Notes) | i 3,541 | i 3,541 | |||||||||
i 2.77%
notes due 2053 (2.77% 2053 Notes) | i 940 | i — | |||||||||
Other notes due 2097 | i 100 | i 100 | |||||||||
Unamortized bond discounts, premiums and issuance costs, net | ( i 1,196) | ( i 868) | |||||||||
Fair value adjustments | i 643 | i 296 | |||||||||
Other | i 5 | i — | |||||||||
Total carrying value of debt | i 34,287 | i 29,903 | |||||||||
Less current portion | ( i 91) | ( i 2,953) | |||||||||
Total long-term debt | $ | i 34,196 | $ | i 26,950 |
September 30, 2020 | December 31, 2019 | |||||||||||||||||||
Notes | Notional amounts | Effective interest rates | Notional amounts | Effective interest rates | ||||||||||||||||
i 3.45% 2020 Notes | $ | i — | LIBOR
+ i 1.1% | $ | i 900 | LIBOR
+ i 1.1% | ||||||||||||||
i 4.10% 2021 Notes | i — | LIBOR
+ i 1.7% | i 1,000 | LIBOR
+ i 1.7% | ||||||||||||||||
i 3.875% 2021 Notes | i 1,450 | LIBOR
+ i 2.0% | i 1,750 | LIBOR
+ i 2.0% | ||||||||||||||||
i 3.625% 2022 Notes | i 750 | LIBOR
+ i 2.7% | i 750 | LIBOR + i 1.6% | ||||||||||||||||
i 3.625%
2024 Notes | i 1,400 | LIBOR + i 3.2% | i 1,400 | LIBOR
+ i 1.4% | ||||||||||||||||
i 3.125% 2025 Notes | i 1,000 | LIBOR
+ i 1.8% | i 1,000 | LIBOR
+ i 0.9% | ||||||||||||||||
i 2.60% 2026 Notes | i 1,250 | LIBOR
+ i 1.8% | i 1,250 | LIBOR
+ i 0.3% | ||||||||||||||||
i 4.663% 2051 Notes(1) | i 1,500 | LIBOR
+ i 2.6% | i 1,500 | LIBOR
+ i 0.0% | ||||||||||||||||
Total notional amounts | $ | i 7,350 | $ | i 9,550 |
Principal amount exchanged | |||||
i 6.375%
2037 Notes | $ | i 74 | |||
i 6.90%
2038 Notes | i 37 | ||||
i 6.40%
2039 Notes | i 133 | ||||
i 5.75%
2040 Notes | i 39 | ||||
i 5.15%
2041 Notes | i 245 | ||||
i 5.65%
2042 Notes | i 72 | ||||
i 5.375%
2043 Notes | i 76 |
2020 | 2019 | ||||||||||||||||||||||
Shares | Dollars | Shares | Dollars | ||||||||||||||||||||
First quarter | i 4.3 | $ | i 933 | i 15.9 | $ | i 3,031 | |||||||||||||||||
Second quarter | i 2.6 | i 591 | i 13.1 | i 2,349 | |||||||||||||||||||
Third quarter | i 3.0 | i 752 | i 6.2 | i 1,170 | |||||||||||||||||||
Total stock repurchases | i 9.9 | $ | i 2,276 | i 35.2 | $ | i 6,550 |
Foreign currency translation | Cash flow hedges | Available-for-sale securities | Other | AOCI | |||||||||||||||||||||||||
Balance as of December 31, 2019 | $ | ( i 718) | $ | i 175 | $ | i 22 | $ | ( i 7) | $ | ( i 528) | |||||||||||||||||||
Foreign currency translation adjustments | ( i 52) | — | — | — | ( i 52) | ||||||||||||||||||||||||
Unrealized (losses) gains | — | ( i 162) | i 8 | i — | ( i 154) | ||||||||||||||||||||||||
Reclassification adjustments to income | — | i 84 | ( i 33) | — | i 51 | ||||||||||||||||||||||||
Other | — | — | — | ( i 2) | ( i 2) | ||||||||||||||||||||||||
Income taxes | i — | i 17 | i 6 | — | i 23 | ||||||||||||||||||||||||
Balance as of March 31, 2020 | ( i 770) | i 114 | i 3 | ( i 9) | ( i 662) | ||||||||||||||||||||||||
Foreign currency translation adjustments | ( i 3) | — | — | — | ( i 3) | ||||||||||||||||||||||||
Unrealized losses | — | ( i 30) | ( i 2) | i — | ( i 32) | ||||||||||||||||||||||||
Reclassification adjustments to income | — | ( i 119) | i — | — | ( i 119) | ||||||||||||||||||||||||
Other | — | — | — | i — | i — | ||||||||||||||||||||||||
Income taxes | i — | i 33 | i — | — | i 33 | ||||||||||||||||||||||||
Balance as of June 30, 2020 | ( i 773) | ( i 2) | i 1 | ( i 9) | ( i 783) | ||||||||||||||||||||||||
Foreign currency translation adjustments | i 14 | — | — | — | i 14 | ||||||||||||||||||||||||
Unrealized gains | — | i 60 | i 1 | i — | i 61 | ||||||||||||||||||||||||
Reclassification adjustments to income | — | ( i 224) | i — | — | ( i 224) | ||||||||||||||||||||||||
Other | — | — | — | ( i 7) | ( i 7) | ||||||||||||||||||||||||
Income taxes | i — | i 36 | i — | — | i 36 | ||||||||||||||||||||||||
Balance as of September 30, 2020 | $ | ( i 759) | $ | ( i 130) | $ | i 2 | $ | ( i 16) | $ | ( i 903) |
Three months ended September 30, | ||||||||||||||||||||
Components of AOCI | 2020 | 2019 | Condensed
Consolidated Statements of Income locations | |||||||||||||||||
Cash flow hedges: | ||||||||||||||||||||
Foreign currency contract gains | $ | i 41 | $ | i 26 | Product sales | |||||||||||||||
Cross-currency swap contract gains (losses) | i 183 | ( i 64) | Interest and other income, net | |||||||||||||||||
i 224 | ( i 38) | Income before income taxes | ||||||||||||||||||
( i 49) | i 8 | Provision for income taxes | ||||||||||||||||||
$ | i 175 | $ | ( i 30) | Net income | ||||||||||||||||
Available-for-sale securities: | ||||||||||||||||||||
Net realized losses | $ | i — | $ | ( i 3) | Interest and other income, net | |||||||||||||||
i — | i — | Provision for income taxes | ||||||||||||||||||
$ | i — | $ | ( i 3) | Net income |
Nine months ended September 30, | ||||||||||||||||||||
Components of AOCI | 2020 | 2019 | Condensed
Consolidated Statements of Income locations | |||||||||||||||||
Cash flow hedges: | ||||||||||||||||||||
Foreign currency contract gains | $ | i 158 | $ | i 62 | Product sales | |||||||||||||||
Cross-currency swap contract gains (losses) | i 101 | ( i 92) | Interest and other income, net | |||||||||||||||||
i 259 | ( i 30) | Income before income taxes | ||||||||||||||||||
( i 57) | i 6 | Provision for income taxes | ||||||||||||||||||
$ | i 202 | $ | ( i 24) | Net income | ||||||||||||||||
Available-for-sale securities: | ||||||||||||||||||||
Net realized gains (losses) | $ | i 33 | $ | ( i 9) | Interest and other income, net | |||||||||||||||
( i 7) | i — | Provision for income taxes | ||||||||||||||||||
$ | i 26 | $ | ( i 9) | Net income |
Level 1 | — | Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access | ||||||
Level 2 | — | Valuations for which all significant inputs are observable either directly or indirectly—other than Level 1 inputs | ||||||
Level 3 | — | Valuations based on inputs that are unobservable and significant to the overall fair value measurement |
Quoted prices in active markets for identical assets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) | ||||||||||||||||||||||||
Fair value measurement as of September 30, 2020, using: | Total | |||||||||||||||||||||||||
Assets: | ||||||||||||||||||||||||||
Available-for-sale securities: | ||||||||||||||||||||||||||
U.S. Treasury notes | $ | i 174 | $ | i — | $ | i — | $ | i 174 | ||||||||||||||||||
U.S. Treasury bills | i 6,399 | i — | i — | i 6,399 | ||||||||||||||||||||||
Corporate debt securities: | ||||||||||||||||||||||||||
Financial | i — | i — | i — | i — | ||||||||||||||||||||||
Industrial | i — | i — | i — | i — | ||||||||||||||||||||||
Other | i — | i — | i — | i — | ||||||||||||||||||||||
Residential-mortgage-backed securities | i — | i — | i — | i — | ||||||||||||||||||||||
Money market mutual funds | i 5,016 | i — | i — | i 5,016 | ||||||||||||||||||||||
Other short-term interest-bearing securities | i — | i — | i — | i — | ||||||||||||||||||||||
Equity securities | i 376 | i — | i — | i 376 | ||||||||||||||||||||||
Derivatives: | ||||||||||||||||||||||||||
Foreign currency contracts | i — | i 111 | i — | i 111 | ||||||||||||||||||||||
Cross-currency swap contracts | i — | i 124 | i — | i 124 | ||||||||||||||||||||||
Interest rate swap contracts | i — | i 109 | i — | i 109 | ||||||||||||||||||||||
Total assets | $ | i 11,965 | $ | i 344 | $ | i — | $ | i 12,309 | ||||||||||||||||||
Liabilities: | ||||||||||||||||||||||||||
Derivatives: | ||||||||||||||||||||||||||
Foreign currency contracts | $ | i — | $ | i 88 | $ | i — | $ | i 88 | ||||||||||||||||||
Cross-currency swap contracts | i — | i 481 | i — | i 481 | ||||||||||||||||||||||
Interest rate swap contracts | i — | i 4 | i — | i 4 | ||||||||||||||||||||||
Contingent
consideration obligations | i — | i — | i 54 | i 54 | ||||||||||||||||||||||
Total liabilities | $ | i — | $ | i 573 | $ | i 54 | $ | i 627 |
Quoted prices
in active markets for identical assets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) | ||||||||||||||||||||||||
Fair value measurement as of December 31, 2019, using: | Total | |||||||||||||||||||||||||
Assets: | ||||||||||||||||||||||||||
Available-for-sale securities: | ||||||||||||||||||||||||||
U.S. Treasury notes | $ | i 360 | $ | i — | $ | i — | $ | i 360 | ||||||||||||||||||
U.S. Treasury bills | i — | i — | i — | i — | ||||||||||||||||||||||
Corporate debt securities: | ||||||||||||||||||||||||||
Financial | i — | i 1,121 | i — | i 1,121 | ||||||||||||||||||||||
Industrial | i — | i 834 | i — | i 834 | ||||||||||||||||||||||
Other | i — | i 198 | i — | i 198 | ||||||||||||||||||||||
Residential-mortgage-backed securities | i — | i 182 | i — | i 182 | ||||||||||||||||||||||
Money market mutual funds | i 5,250 | i — | i — | i 5,250 | ||||||||||||||||||||||
Other short-term interest-bearing securities | i — | i 289 | i — | i 289 | ||||||||||||||||||||||
Equity securities | i 303 | i — | i — | i 303 | ||||||||||||||||||||||
Derivatives: | ||||||||||||||||||||||||||
Foreign currency contracts | i — | i 224 | i — | i 224 | ||||||||||||||||||||||
Cross-currency swap contracts | i — | i 66 | i — | i 66 | ||||||||||||||||||||||
Interest rate swap contracts | i — | i 259 | i — | i 259 | ||||||||||||||||||||||
Total assets | $ | i 5,913 | $ | i 3,173 | $ | i — | $ | i 9,086 | ||||||||||||||||||
Liabilities: | ||||||||||||||||||||||||||
Derivatives: | ||||||||||||||||||||||||||
Foreign currency contracts | $ | i — | $ | i 31 | $ | i — | $ | i 31 | ||||||||||||||||||
Cross-currency swap contracts | i — | i 315 | i — | i 315 | ||||||||||||||||||||||
Interest rate swap contracts | i — | i — | i — | i — | ||||||||||||||||||||||
Contingent
consideration obligations | i — | i — | i 61 | i 61 | ||||||||||||||||||||||
Total liabilities | $ | i — | $ | i 346 | $ | i 61 | $ | i 407 |
Foreign currency | U.S. dollars | |||||||||||||||||||||||||
Hedged notes | Notional amounts | Interest rates | Notional amounts | Interest rates | ||||||||||||||||||||||
1.25% 2022 euro Notes | € | i 1,250 | i 1.3 | % | $ | i 1,388 | i 3.2 | % | ||||||||||||||||||
0.41% 2023 Swiss franc Bonds | CHF | i 700 | i 0.4 | % | $ | i 704 | i 3.4 | % | ||||||||||||||||||
2.00% 2026 euro Notes | € | i 750 | i 2.0 | % | $ | i 833 | i 3.9 | % | ||||||||||||||||||
5.50% 2026 pound sterling Notes | £ | i 475 | i 5.5 | % | $ | i 747 | i 6.0 | % | ||||||||||||||||||
4.00% 2029 pound sterling Notes | £ | i 700 | i 4.0 | % | $ | i 1,111 | i 4.5 | % |
Three
months ended September 30, | Nine months ended September 30, | |||||||||||||||||||||||||
Derivatives in cash flow hedging relationships | 2020 | 2019 | 2020 | 2019 | ||||||||||||||||||||||
Foreign currency contracts | $ | ( i 163) | $ | i 176 | $ | ( i 25) | $ | i 245 | ||||||||||||||||||
Cross-currency swap contracts | i 223 | ( i 105) | ( i 107) | ( i 240) | ||||||||||||||||||||||
Total unrealized gains (losses) | $ | i 60 | $ | i 71 | $ | ( i 132) | $ | i 5 |
Carrying amounts of hedged liabilities(1) | Cumulative
amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities(2) | |||||||||||||||||||||||||
Condensed Consolidated Balance Sheets locations | September 30, 2020 | December 31, 2019 | September 30, 2020 | December 31, 2019 | ||||||||||||||||||||||
Current portion of long-term debt | $ | i 89 | $ | i 903 | $ | i 89 | $ | i 4 | ||||||||||||||||||
Long-term debt | $ | i 7,782 | $ | i 8,814 | $ | i 554 | $ | i 292 |
Three months ended September 30, 2020 | Nine months ended September 30, 2020 | |||||||||||||||||||||||||||||||||||||
Product sales | Interest and other income, net | Interest (expense), net | Product sales | Interest and other income, net | Interest (expense), net | |||||||||||||||||||||||||||||||||
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income | $ | i 6,104 | $ | i 55 | $ | ( i 302) | $ | i 17,906 | $ | i 69 | $ | ( i 944) | ||||||||||||||||||||||||||
The effects of cash flow and fair value hedging: | ||||||||||||||||||||||||||||||||||||||
Gains on cash flow hedging relationships reclassified out of AOCI: | ||||||||||||||||||||||||||||||||||||||
Foreign currency contracts | $ | i 41 | $ | — | $ | — | $ | i 158 | $ | — | $ | — | ||||||||||||||||||||||||||
Cross-currency swap contracts | $ | — | $ | i 183 | $ | — | $ | — | $ | i 101 | $ | — | ||||||||||||||||||||||||||
Gains (losses) on fair value hedging relationships—interest rate swap agreements: | ||||||||||||||||||||||||||||||||||||||
Hedged items(1) | $ | — | $ | — | $ | i 35 | $ | — | $ | — | $ | i 215 | ||||||||||||||||||||||||||
Derivatives designated as hedging instruments | $ | — | $ | — | $ | ( i 13) | $ | — | $ | — | $ | ( i 150) |
Three months ended September 30, 2019 | Nine months ended September 30, 2019 | |||||||||||||||||||||||||||||||||||||
Product sales | Interest and other income, net | Interest (expense), net | Product sales | Interest and other income, net | Interest (expense), net | |||||||||||||||||||||||||||||||||
Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income | $ | i 5,463 | $ | i 114 | $ | ( i 313) | $ | i 16,323 | $ | i 517 | $ | ( i 988) | ||||||||||||||||||||||||||
The effects of cash flow and fair value hedging: | ||||||||||||||||||||||||||||||||||||||
Gains (losses) on cash flow hedging relationships reclassified out of AOCI: | ||||||||||||||||||||||||||||||||||||||
Foreign currency contracts | $ | i 26 | $ | — | $ | — | $ | i 62 | $ | — | $ | — | ||||||||||||||||||||||||||
Cross-currency swap contracts | $ | — | $ | ( i 64) | $ | — | $ | — | $ | ( i 92) | $ | — | ||||||||||||||||||||||||||
(Losses) gains on fair value hedging relationships—interest rate swap agreements: | ||||||||||||||||||||||||||||||||||||||
Hedged items(1) | $ | — | $ | — | $ | ( i 96) | $ | — | $ | — | $ | ( i 444) | ||||||||||||||||||||||||||
Derivatives designated as hedging instruments | $ | — | $ | — | $ | i 96 | $ | — | $ | — | $ | i 447 |
Derivative assets | Derivative liabilities | |||||||||||||||||||||||||
September 30, 2020 | Condensed Consolidated Balance Sheets locations | Fair values | Condensed Consolidated Balance Sheets locations | Fair values | ||||||||||||||||||||||
Derivatives designated as hedging instruments: | ||||||||||||||||||||||||||
Foreign currency contracts | Other current assets/ Other assets | $ | i 111 | Accrued liabilities/ Other noncurrent liabilities | $ | i 88 | ||||||||||||||||||||
Cross-currency swap contracts | Other current assets/ Other assets | i 124 | Accrued liabilities/ Other noncurrent liabilities | i 481 | ||||||||||||||||||||||
Interest rate swap contracts | Other current assets/ Other assets | i 109 | Accrued liabilities/ Other noncurrent liabilities | i 4 | ||||||||||||||||||||||
Total
derivatives designated as hedging instruments | i 344 | i 573 | ||||||||||||||||||||||||
Derivatives
not designated as hedging instruments: | ||||||||||||||||||||||||||
Foreign currency contracts | Other current assets | i — | Accrued
liabilities | i — | ||||||||||||||||||||||
Total derivatives not designated as hedging instruments | i — | i — | ||||||||||||||||||||||||
Total derivatives | $ | i 344 | $ | i 573 |
Derivative assets | Derivative liabilities | |||||||||||||||||||||||||
December 31, 2019 | Condensed Consolidated Balance Sheets locations | Fair values | Condensed Consolidated Balance Sheets locations | Fair values | ||||||||||||||||||||||
Derivatives designated as hedging instruments: | ||||||||||||||||||||||||||
Foreign currency contracts | Other current assets/ Other assets | $ | i 223 | Accrued liabilities/ Other noncurrent liabilities | $ | i 31 | ||||||||||||||||||||
Cross-currency swap contracts | Other current assets/ Other assets | i 66 | Accrued liabilities/ Other noncurrent liabilities | i 315 | ||||||||||||||||||||||
Interest rate swap contracts | Other current assets/ Other assets | i 259 | Accrued liabilities/ Other noncurrent liabilities | i — | ||||||||||||||||||||||
Total
derivatives designated as hedging instruments | i 548 | i 346 | ||||||||||||||||||||||||
Derivatives
not designated as hedging instruments: | ||||||||||||||||||||||||||
Foreign currency contracts | Other current assets | i 1 | Accrued liabilities | i — | ||||||||||||||||||||||
Total derivatives not designated as hedging instruments | i 1 | i — | ||||||||||||||||||||||||
Total derivatives | $ | i 549 | $ | i 346 |
Item 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
Three
months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||||||||||||||
2020 | 2019 | Change | 2020 | 2019 | Change | ||||||||||||||||||||||||||||||
Product sales | |||||||||||||||||||||||||||||||||||
U.S. | $ | 4,618 | $ | 4,029 | 15 | % | $ | 13,325 | $ | 12,162 | 10 | % | |||||||||||||||||||||||
ROW | 1,486 | 1,434 | 4 | % | 4,581 | 4,161 | 10 | % | |||||||||||||||||||||||||||
Total product sales | 6,104 | 5,463 | 12 | % | 17,906 | 16,323 | 10 | % | |||||||||||||||||||||||||||
Other revenues | 319 | 274 | 16 | % | 884 | 842 | 5 | % | |||||||||||||||||||||||||||
Total revenues | $ | 6,423 | $ | 5,737 | 12 | % | $ | 18,790 | $ | 17,165 | 9 | % | |||||||||||||||||||||||
Operating expenses | $ | 3,970 | $ | 3,261 | 22 | % | $ | 11,659 | $ | 9,539 | 22 | % | |||||||||||||||||||||||
Operating income | $ | 2,453 | $ | 2,476 | (1) | % | $ | 7,131 | $ | 7,626 | (6) | % | |||||||||||||||||||||||
Net income | $ | 2,021 | $ | 1,968 | 3 | % | $ | 5,649 | $ | 6,139 | (8) | % | |||||||||||||||||||||||
Diluted EPS | $ | 3.43 | $ | 3.27 | 5 | % | $ | 9.54 | $ | 10.01 | (5) | % | |||||||||||||||||||||||
Diluted shares | 589 | 602 | (2) | % | 592 | 613 | (3) | % |
Three
months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||||||||||||||
2020 | 2019 | Change | 2020 | 2019 | Change | ||||||||||||||||||||||||||||||
ENBREL | $ | 1,325 | $ | 1,366 | (3) | % | $ | 3,724 | $ | 3,880 | (4) | % | |||||||||||||||||||||||
Prolia® | 701 | 630 | 11 | % | 2,014 | 1,920 | 5 | % | |||||||||||||||||||||||||||
Neulasta® | 555 | 711 | (22) | % | 1,757 | 2,556 | (31) | % | |||||||||||||||||||||||||||
Otezla® | 538 | — | N/A | 1,578 | — | N/A | |||||||||||||||||||||||||||||
XGEVA® | 481 | 476 | 1 | % | 1,397 | 1,446 | (3) | % | |||||||||||||||||||||||||||
Aranesp® | 384 | 452 | (15) | % | 1,193 | 1,302 | (8) | % | |||||||||||||||||||||||||||
KYPROLIS® | 260 | 266 | (2) | % | 793 | 778 | 2 | % | |||||||||||||||||||||||||||
Repatha® | 205 | 168 | 22 | % | 634 | 461 | 38 | % | |||||||||||||||||||||||||||
Other products | 1,655 | 1,394 | 19 | % | 4,816 | 3,980 | 21 | % | |||||||||||||||||||||||||||
Total product sales | $ | 6,104 | $ | 5,463 | 12 | % | $ | 17,906 | $ | 16,323 | 10 | % |
Three
months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||||||||||||||
2020 | 2019 | Change | 2020 | 2019 | Change | ||||||||||||||||||||||||||||||
ENBREL — U.S. | $ | 1,289 | $ | 1,323 | (3) | % | $ | 3,619 | $ | 3,744 | (3) | % | |||||||||||||||||||||||
ENBREL — Canada | 36 | 43 | (16) | % | 105 | 136 | (23) | % | |||||||||||||||||||||||||||
Total ENBREL | $ | 1,325 | $ | 1,366 | (3) | % | $ | 3,724 | $ | 3,880 | (4) | % |
Three
months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||||||||||||||
2020 | 2019 | Change | 2020 | 2019 | Change | ||||||||||||||||||||||||||||||
Prolia® — U.S. | $ | 478 | $ | 425 | 12 | % | $ | 1,341 | $ | 1,273 | 5 | % | |||||||||||||||||||||||
Prolia® — ROW | 223 | 205 | 9 | % | 673 | 647 | 4 | % | |||||||||||||||||||||||||||
Total
Prolia® | $ | 701 | $ | 630 | 11 | % | $ | 2,014 | $ | 1,920 | 5 | % |
Three
months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||||||||||||||
2020 | 2019 | Change | 2020 | 2019 | Change | ||||||||||||||||||||||||||||||
Neulasta®—
U.S. | $ | 484 | $ | 619 | (22) | % | $ | 1,538 | $ | 2,231 | (31) | % | |||||||||||||||||||||||
Neulasta®— ROW | 71 | 92 | (23) | % | 219 | 325 | (33) | % | |||||||||||||||||||||||||||
Total
Neulasta® | $ | 555 | $ | 711 | (22) | % | $ | 1,757 | $ | 2,556 | (31) | % |
Three months ended September 30, | Nine
months ended September 30, | ||||||||||||||||||||||||||||||||||
2020 | 2019 | Change | 2020 | 2019 | Change | ||||||||||||||||||||||||||||||
Otezla® — U.S. | $ | 439 | $ | — | N/A | $ | 1,280 | $ | — | N/A | |||||||||||||||||||||||||
Otezla® — ROW | 99 | — | N/A | 298 | — | N/A | |||||||||||||||||||||||||||||
Total
Otezla® | $ | 538 | $ | — | N/A | $ | 1,578 | $ | — | N/A |
Three
months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||||||||||||||
2020 | 2019 | Change | 2020 | 2019 | Change | ||||||||||||||||||||||||||||||
XGEVA® — U.S. | $ | 363 | $ | 356 | 2 | % | $ | 1,036 | $ | 1,091 | (5) | % | |||||||||||||||||||||||
XGEVA® — ROW | 118 | 120 | (2) | % | 361 | 355 | 2 | % | |||||||||||||||||||||||||||
Total
XGEVA® | $ | 481 | $ | 476 | 1 | % | $ | 1,397 | $ | 1,446 | (3) | % |
Three
months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||||||||||||||
2020 | 2019 | Change | 2020 | 2019 | Change | ||||||||||||||||||||||||||||||
Aranesp®
— U.S. | $ | 158 | $ | 204 | (23) | % | $ | 489 | $ | 578 | (15) | % | |||||||||||||||||||||||
Aranesp® — ROW | 226 | 248 | (9) | % | 704 | 724 | (3) | % | |||||||||||||||||||||||||||
Total
Aranesp® | $ | 384 | $ | 452 | (15) | % | $ | 1,193 | $ | 1,302 | (8) | % |
Three
months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||||||||||||||
2020 | 2019 | Change | 2020 | 2019 | Change | ||||||||||||||||||||||||||||||
KYPROLIS®
— U.S. | $ | 173 | $ | 163 | 6 | % | $ | 527 | $ | 483 | 9 | % | |||||||||||||||||||||||
KYPROLIS® — ROW | 87 | 103 | (16) | % | 266 | 295 | (10) | % | |||||||||||||||||||||||||||
Total
KYPROLIS® | $ | 260 | $ | 266 | (2) | % | $ | 793 | $ | 778 | 2 | % |
Three
months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||||||||||||||
2020 | 2019 | Change | 2020 | 2019 | Change | ||||||||||||||||||||||||||||||
Repatha®
— U.S. | $ | 92 | $ | 85 | 8 | % | $ | 331 | $ | 259 | 28 | % | |||||||||||||||||||||||
Repatha® — ROW | 113 | 83 | 36 | % | 303 | 202 | 50 | % | |||||||||||||||||||||||||||
Total
Repatha® | $ | 205 | $ | 168 | 22 | % | $ | 634 | $ | 461 | 38 | % |
Three
months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||||||||||||||
2020 | 2019 | Change | 2020 | 2019 | Change | ||||||||||||||||||||||||||||||
Nplate®—
U.S. | $ | 118 | $ | 119 | (1) | % | $ | 352 | $ | 355 | (1) | % | |||||||||||||||||||||||
Nplate®— ROW | 94 | 76 | 24 | % | 271 | 230 | 18 | % | |||||||||||||||||||||||||||
Vectibix®—
U.S. | 90 | 79 | 14 | % | 249 | 236 | 6 | % | |||||||||||||||||||||||||||
Vectibix®— ROW | 103 | 117 | (12) | % | 341 | 326 | 5 | % | |||||||||||||||||||||||||||
Parsabiv®
— U.S. | 156 | 137 | 14 | % | 462 | 394 | 17 | % | |||||||||||||||||||||||||||
Parsabiv® — ROW | 27 | 20 | 35 | % | 82 | 57 | 44 | % | |||||||||||||||||||||||||||
MVASI®—
U.S. | 185 | 42 | * | 442 | 42 | * | |||||||||||||||||||||||||||||
MVASI®— ROW | 46 | 1 | * | 76 | 1 | * | |||||||||||||||||||||||||||||
EPOGEN®
— U.S. | 149 | 215 | (31) | % | 465 | 657 | (29) | % | |||||||||||||||||||||||||||
KANJINTI®— U.S. | 149 | 39 | * | 346 | 39 | * | |||||||||||||||||||||||||||||
KANJINTI®—
ROW | 18 | 30 | (40) | % | 63 | 84 | (25) | % | |||||||||||||||||||||||||||
BLINCYTO® — U.S. | 54 | 47 | 15 | % | 167 | 126 | 33 | % | |||||||||||||||||||||||||||
BLINCYTO®
— ROW | 35 | 38 | (8) | % | 109 | 106 | 3 | % | |||||||||||||||||||||||||||
Aimovig® — U.S. | 105 | 66 | 59 | % | 274 | 208 | 32 | % | |||||||||||||||||||||||||||
EVENITY®
— U.S. | 54 | 12 | * | 131 | 15 | * | |||||||||||||||||||||||||||||
EVENITY®— ROW | 5 | 47 | (89) | % | 129 | 89 | 45 | % | |||||||||||||||||||||||||||
Sensipar®
— U.S. | 7 | 38 | (82) | % | 81 | 216 | (63) | % | |||||||||||||||||||||||||||
Sensipar®/Mimpara® — ROW | 32 | 71 | (55) | % | 162 | 228 | (29) | % | |||||||||||||||||||||||||||
AMGEVITATM
— ROW | 80 | 61 | 31 | % | 228 | 144 | 58 | % | |||||||||||||||||||||||||||
NEUPOGEN®— U.S. | 44 | 32 | 38 | % | 117 | 137 | (15) | % | |||||||||||||||||||||||||||
NEUPOGEN®—
ROW | 21 | 22 | (5) | % | 62 | 65 | (5) | % | |||||||||||||||||||||||||||
Other — U.S. | 31 | 28 | 11 | % | 78 | 78 | — | % | |||||||||||||||||||||||||||
Other — ROW | 52 | 57 | (9) | % | 129 | 147 | (12) | % | |||||||||||||||||||||||||||
Total other products | $ | 1,655 | $ | 1,394 | 19 | % | $ | 4,816 | $ | 3,980 | 21 | % | |||||||||||||||||||||||
Total U.S. — other products | $ | 1,142 | $ | 854 | 34 | % | $ | 3,164 | $ | 2,503 | 26 | % | |||||||||||||||||||||||
Total ROW — other products | 513 | 540 | (5) | % | 1,652 | 1,477 | 12 | % | |||||||||||||||||||||||||||
Total other products | $ | 1,655 | $ | 1,394 | 19 | % | $ | 4,816 | $ | 3,980 | 21 | % |
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||||||||||||||
2020 | 2019 | Change | 2020 | 2019 | Change | ||||||||||||||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||||||||||||||
Cost
of sales | $ | 1,561 | $ | 1,036 | 51 | % | $ | 4,562 | $ | 3,103 | 47 | % | |||||||||||||||||||||||
% of product sales | 25.6 | % | 19.0 | % | 25.5 | % | 19.0 | % | |||||||||||||||||||||||||||
% of total revenues | 24.3 | % | 18.1 | % | 24.3 | % | 18.1 | % | |||||||||||||||||||||||||||
Research and development | $ | 1,062 | $ | 1,001 | 6 | % | $ | 2,978 | $ | 2,804 | 6 | % | |||||||||||||||||||||||
% of product sales | 17.4 | % | 18.3 | % | 16.6 | % | 17.2 | % | |||||||||||||||||||||||||||
% of total revenues | 16.5 | % | 17.4 | % | 15.8 | % | 16.3 | % | |||||||||||||||||||||||||||
Selling, general and administrative | $ | 1,346 | $ | 1,223 | 10 | % | $ | 3,957 | $ | 3,637 | 9 | % | |||||||||||||||||||||||
% of product sales | 22.1 | % | 22.4 | % | 22.1 | % | 22.3 | % | |||||||||||||||||||||||||||
% of total revenues | 21.0 | % | 21.3 | % | 21.1 | % | 21.2 | % | |||||||||||||||||||||||||||
Other | $ | 1 | $ | 1 | — | % | $ | 162 | $ | (5) | * |
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||||
2020 | 2019 | 2020 | 2019 | ||||||||||||||||||||
Interest expense, net | $ | 302 | $ | 313 | $ | 944 | $ | 988 | |||||||||||||||
Interest and other income, net | $ | 55 | $ | 114 | $ | 69 | $ | 517 | |||||||||||||||
Provision for income taxes | $ | 185 | $ | 309 | $ | 607 | $ | 1,016 | |||||||||||||||
Effective tax rate | 8.4 | % | 13.6 | % | 9.7 | % | 14.2 | % |
September 30, 2020 | December 31, 2019 | ||||||||||
Cash, cash equivalents and marketable securities | $ | 12,360 | $ | 8,911 | |||||||
Total assets | $ | 64,637 | $ | 59,707 | |||||||
Current portion of long-term debt | $ | 91 | $ | 2,953 | |||||||
Long-term debt | $ | 34,196 | $ | 26,950 | |||||||
Stockholders’ equity | $ | 10,959 | $ | 9,673 |
Nine months ended September 30, | |||||||||||
2020 | 2019 | ||||||||||
Net cash provided by operating activities | $ | 8,344 | $ | 6,636 | |||||||
Net cash (used in) provided by investing activities | $ | (4,017) | $ | 11,672 | |||||||
Net cash used in financing activities | $ | (1,277) | $ | (13,838) |
Item 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
Item 4. | CONTROLS AND PROCEDURES |
Item 1. | LEGAL PROCEEDINGS |
Item 1A. | RISK FACTORS |
Item 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
Period | Total
number of shares purchased | Average price paid per share (1) | Total number of shares purchased as part of publicly announced program | Maximum dollar value that may yet be purchased under the program(2) | ||||||||||||||||||||||
July 1 - 31 | 1,069,984 | $ | 252.92 | 1,069,984 | $ | 4,678,996,437 | ||||||||||||||||||||
August 1 - 31 | 1,004,844 | $ | 242.72 | 1,004,844 | $ | 4,435,099,357 | ||||||||||||||||||||
September 1 - 30 | 960,100 | $ | 246.50 | 960,100 | $ | 4,198,437,082 | ||||||||||||||||||||
Total | 3,034,928 | $ | 247.51 | 3,034,928 |
Item 6. | EXHIBITS |
10.48 | Amendment
No. 1 to the Collaboration Agreement, dated October 1, 2014, by and among Amgen Inc., AstraZeneca Collaboration Ventures, LLC and AstraZeneca Pharmaceuticals LP (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (Filed as an exhibit to Form 10-K for the year ended December 31, 2014 on February 19, 2015 and incorporated herein by reference.) | |||||||
10.49 | Amendment Nos.
2 through 6 to the March 30, 2012 Collaboration Agreement between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, dated May 2 and 27 and October 2, 2016, January 31, 2018, and May 15, 2020, respectively (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2020 on July 29, 2020 and incorporated herein by reference.) | |||||||
31* | ||||||||
32** | ||||||||
101.INS | Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document. | |||||||
101.SCH* | Inline XBRL Taxonomy Extension Schema Document. | |||||||
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |||||||
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |||||||
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document. | |||||||
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |||||||
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
Amgen Inc. | ||||||||||||||
(Registrant) | ||||||||||||||
Date: | October 28, 2020 | By: | /S/ PETER H. GRIFFITH | |||||||||||
Peter H. Griffith | ||||||||||||||
Executive Vice President and Chief Financial Officer | ||||||||||||||
(Principal Financial Officer) |
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
12/31/27 | ||||
12/31/25 | ||||
12/31/24 | ||||
12/31/23 | ||||
12/31/22 | ||||
12/31/21 | 10-K | |||
6/14/21 | ||||
2/21/21 | ||||
12/31/20 | 10-K, 11-K | |||
12/9/20 | ||||
12/8/20 | ||||
Filed as of: | 10/29/20 | |||
Filed on: | 10/28/20 | 8-K | ||
10/23/20 | ||||
10/21/20 | ||||
10/14/20 | ||||
10/13/20 | ||||
10/7/20 | ||||
10/5/20 | ||||
10/1/20 | ||||
For Period end: | 9/30/20 | |||
9/29/20 | ||||
9/24/20 | ||||
9/14/20 | ||||
9/13/20 | ||||
9/8/20 | ||||
8/25/20 | 4 | |||
8/19/20 | 4 | |||
8/18/20 | 4, 8-K | |||
8/14/20 | 8-K | |||
8/6/20 | ||||
8/5/20 | ||||
7/31/20 | 4 | |||
7/29/20 | 10-Q, 3 | |||
7/28/20 | 10-Q, 8-K | |||
7/24/20 | ||||
7/22/20 | 4, 8-K | |||
7/14/20 | ||||
7/10/20 | ||||
6/30/20 | 10-Q | |||
6/9/20 | ||||
6/8/20 | ||||
5/6/20 | 424B2, 8-K | |||
5/1/20 | 10-Q, 4 | |||
3/31/20 | 10-Q, 8-K | |||
3/27/20 | ||||
3/11/20 | ||||
3/6/20 | ||||
2/21/20 | 8-K | |||
2/12/20 | 10-K, SC 13G/A | |||
1/8/20 | SC 13D | |||
1/2/20 | 3, 8-K | |||
1/1/20 | 3 | |||
12/31/19 | 10-K, 10-K/A, 11-K | |||
12/12/19 | 8-K | |||
11/21/19 | 8-K, 8-K/A | |||
10/17/19 | 8-K | |||
9/30/19 | 10-Q | |||
8/26/19 | 8-K | |||
7/31/19 | 10-Q | |||
6/30/19 | 10-Q | |||
3/31/19 | 10-Q | |||
12/31/18 | 10-K, 11-K, 5 | |||
10/31/18 | 10-Q | |||
9/30/18 | 10-Q | |||
4/25/18 | 10-Q, 4, DEFA14A | |||
3/31/18 | 10-Q | |||
2/13/18 | 10-K, SC 13G/A, SC TO-I/A | |||
12/31/17 | 10-K, 11-K, 5 | |||
11/2/17 | 8-K | |||
7/26/17 | 10-Q | |||
6/30/17 | 10-Q | |||
5/11/17 | 8-K | |||
4/27/17 | 10-Q | |||
3/31/17 | 10-Q | |||
2/14/17 | 10-K, S-3ASR, SC 13G | |||
12/31/16 | 10-K, 11-K | |||
10/28/16 | 10-Q | |||
9/30/16 | 10-Q | |||
8/19/16 | 8-K | |||
6/14/16 | 8-K | |||
5/2/16 | 10-Q | |||
3/31/16 | 10-Q, 4 | |||
3/8/16 | 8-K | |||
2/26/16 | ||||
2/17/16 | 8-K | |||
2/15/16 | 8-K | |||
8/5/15 | 10-Q | |||
6/30/15 | 10-Q, 10-Q/A | |||
5/1/15 | 8-K | |||
4/27/15 | 10-Q, 4 | |||
3/31/15 | 10-Q, 4 | |||
2/19/15 | 10-K, 4 | |||
12/31/14 | 10-K, 11-K, 4, ARS | |||
5/22/14 | 4, 8-K | |||
2/24/14 | 10-K, S-3ASR | |||
12/31/13 | 10-K, 11-K, ARS | |||
7/31/13 | 10-K/A | |||
5/3/13 | 10-Q, SC 13G/A | |||
4/8/13 | DEF 14A, DEFA14A | |||
3/31/13 | 10-Q | |||
3/6/13 | 4, 8-K | |||
2/27/13 | 10-K | |||
12/31/12 | 10-K, 10-K/A, 11-K, ARS | |||
9/13/12 | 8-K | |||
5/15/12 | 8-K, CT ORDER | |||
5/8/12 | 10-Q | |||
3/31/12 | 10-Q | |||
2/27/12 | ||||
12/31/11 | 10-K, 11-K, 5, ARS | |||
12/5/11 | 8-K | |||
11/10/11 | 8-K, SC TO-I/A | |||
6/30/11 | 10-Q, 8-K | |||
5/10/11 | 10-Q | |||
3/31/11 | 10-Q | |||
9/17/10 | 8-K | |||
3/12/10 | 4, 8-K | |||
12/31/09 | 10-K, 11-K, 5, ARS | |||
5/8/09 | 4, 8-K | |||
1/16/09 | 5, 8-K | |||
11/7/08 | 10-Q | |||
9/30/08 | 10-Q | |||
5/23/08 | 8-K, REGDEX | |||
2/28/08 | 10-K | |||
12/31/07 | 10-K, 11-K, ARS | |||
5/30/07 | 8-K | |||
5/10/06 | 10-Q, 8-K, DEF 14A | |||
3/31/06 | 10-Q | |||
8/4/03 | 4, S-3 | |||
5/13/98 | 10-Q | |||
3/31/98 | 10-Q | |||
5/14/97 | 10-Q | |||
4/8/97 | 8-K | |||
3/31/97 | 10-Q | |||
3/14/97 | 8-K | |||
1/1/92 | ||||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/03/24 Amgen Inc. 10-Q 3/31/24 81:8.5M 2/14/24 Amgen Inc. 10-K 12/31/23 159:22M 10/31/23 Amgen Inc. 10-Q 9/30/23 85:10M 8/04/23 Amgen Inc. 10-Q 6/30/23 86:10M 4/28/23 Amgen Inc. 10-Q 3/31/23 82:9.6M 2/09/23 Amgen Inc. 10-K 12/31/22 144:21M 11/04/22 Amgen Inc. 10-Q 9/30/22 81:10M 8/05/22 Amgen Inc. 10-Q 6/30/22 82:12M 4/28/22 Amgen Inc. 10-Q 3/31/22 77:9M 2/16/22 Amgen Inc. 10-K 12/31/21 139:19M 11/03/21 Amgen Inc. 10-Q 9/30/21 80:11M 8/04/21 Amgen Inc. 10-Q 6/30/21 79:11M 4/28/21 Amgen Inc. 10-Q 3/31/21 74:8.3M 2/09/21 Amgen Inc. 10-K 12/31/20 140:20M |